Menu

Some Human Cancers Exhibit Low-grade Inflammation

NSAIDs reduce this "parainflammation," hinting at how they help lower cancer risk.

Oct 1, 2016
Alison F. Takemura

SIMMER DOWN: A mouse adenoma organoid treated with an NSAID (right) has less parainflammation (orange marker; control on the left). HEBREW UNIVERSITY OF JERUSALEM, AUDREY LASRY AND GENOME BIOL, 17:145, 2016

EDITOR'S CHOICE IN CELL & MOLECULAR BIOLOGY

The paper
D. Aran et al., “Widespread parainflammation in human cancer,” Genome Biol, 17:145, 2016.

Smoldering threat
Researchers in Israel were trying to understand why a particular mouse model was so unusually cancer-prone once it suffered a mutation in the tumor suppressor gene p53. They noticed that the animal’s epithelial tissue showed signs of low-grade inflammation, undetectable by normal hallmarks such as white blood cell recruitment. Intriguingly, treating the mutated mouse with a nonsteroidal anti-inflammatory drug (NSAID) reduced its risk of cancer—an effect observed in some human studies as well.

Smoke signals
To explore what was driving this so-called parainflammation (PI), the team recently collaborated with Dvir Aran of the University of California, San Francisco, and colleagues to identify its genetic signature, and found an upregulation of 40 genes. The researchers then analyzed gene expression data from more than 800 human cancer cell lines and from about 6,500 patient tumor samples, including 18 cancer types, to uncover whether any harbored this signature.

Striking a match
By scoring gene expression data based on their similarity to the PI signature, the team found four cancers—including lung and pancreatic adenocarcinomas—with notably higher tallies. Mutations in p53 were also associated with a higher PI score. The prognoses for these cancers were dramatically worse, suggesting PI might exacerbate cancer progression.

Cooling cancer
When the team treated mouse adenoma organoids and two human cancer cell lines with an NSAID, the expression of PI genes fell by more than half. The findings could translate to the clinic, by helping to identify patients who would benefit from NSAID treatment, says Michael Karin, who studies inflammation in colorectal cancer at UC San Diego. “Right now, nobody is stratifying the patients,” he says.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Complete Pathology Solutions: Make Every Minute Count

Complete Pathology Solutions: Make Every Minute Count

From sample collection and handling, to fixation and processing, tissue staining, and covering all your IHC and water purification needs—you can have confidence in the quality of your results with MilliporeSigma's one-stop pathology solution.

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.